Aurinia Pharmaceuticals Inc.
Moat Score — Aurinia Pharmaceuticals Inc.
Total Moat Score
13 / 30
| Moat Factor | Score | Analysis |
|---|---|---|
| Intangible Assets Patents, trademarks, brand strength, or regulatory licenses that protect a company's products or services from being freely copied by competitors. | 4 / 5 | Aurinia holds patent protection and regulatory exclusivity around LUPKYNIS as the first FDA-approved oral therapy specifically for lupus nephritis, backed by a substantial pivotal clinical trial data package that would be costly for any generic or competing entrant to replicate before patent expiry. |
| Cost Advantage A durable ability to produce goods or services more cheaply than competitors — through scale, unique access to cheap inputs, location, or process — that lets a company undercut rivals or out-earn them at the same price. | 2 / 5 | As a single-product specialty biopharma, Aurinia benefits from a lean, focused commercial infrastructure relative to its revenue base, though it lacks the scale cost advantages of large diversified pharmaceutical companies. |
| Pricing Power The ability to raise prices without losing meaningful business, because the product or service is differentiated, mission-critical, or has few good substitutes. | 3 / 5 | As the first and only oral therapy specifically indicated for lupus nephritis, Aurinia has meaningful specialty drug pricing power, tempered by payer scrutiny and competition from GSK's Benlysta and generic background immunosuppressants. |
| Network Effect The product or service becomes more valuable to every user as more people or organizations use it, making an established leader harder to displace. | 0 / 5 | Pharmaceutical commercialization exhibits no network effect between patients or prescribers. |
| Switching Costs The money, time, or operational disruption a customer would face switching to a competitor, which locks in existing customers and supports renewals. | 2 / 5 | Once nephrologists and patients establish a treatment regimen incorporating LUPKYNIS, there is some clinical inertia favoring continuity, but physicians can and do adjust regimens based on evolving evidence and competitive options like Benlysta. |
| Efficient Scale A market that can only profitably support a small number of players, so incumbents face limited threat from new entrants even without other defenses. | 2 / 5 | The lupus nephritis specialist prescriber base is relatively small and concentrated, allowing an efficient, focused commercial model, though the overall autoimmune kidney disease treatment market includes well-resourced large pharma competitors like GSK. |